Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900
联合用药方案为口服生物可利用的选择性 ChK1 抑制剂 GNE-900 对吉西他滨的化学增强作用定义了一个“机会窗口”
期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-12-1218
Elizabeth Blackwood, Jennifer Epler, Ivana Yen, Michael Flagella, Tom O'Brien, Marie Evangelista, Stephen Schmidt, Yang Xiao, Jonathan Choi, Kaska Kowanetz, Judi Ramiscal, Kenton Wong, Diana Jakubiak, Sharon Yee, Gary Cain, Lewis Gazzard, Karen Williams, Jason Halladay, Peter K Jackson, Shiva Malek
